NBTK.DE vs. CIB0.DE
NBTK.DE (Invesco Nasdaq Biotech UCITS ETF) and CIB0.DE (VanEck Bionic Engineering UCITS ETF A) are both Health & Biotech Equities funds - NBTK.DE tracks the Nasdaq Biotechnology while CIB0.DE tracks the MVIS Global Bionic Healthcare ESG. Both are passively managed. Over the past 3 years, NBTK.DE returned 14.43%/yr vs -7.77%/yr for CIB0.DE. At a 0.49 correlation, their price movements are largely independent. NBTK.DE charges 0.40%/yr vs 0.55%/yr for CIB0.DE.
Performance
NBTK.DE vs. CIB0.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBTK.DE achieves a 13.45% return, which is significantly higher than CIB0.DE's -11.68% return.
NBTK.DE
- 1D
- 0.00%
- 1M
- 9.34%
- YTD
- 13.45%
- 6M
- 12.97%
- 1Y
- 53.79%
- 3Y*
- 14.43%
- 5Y*
- 5.85%
- 10Y*
- —
CIB0.DE
- 1D
- 0.00%
- 1M
- 2.50%
- YTD
- -11.68%
- 6M
- -11.71%
- 1Y
- -10.87%
- 3Y*
- -7.77%
- 5Y*
- —
- 10Y*
- —
NBTK.DE vs. CIB0.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
NBTK.DE Invesco Nasdaq Biotech UCITS ETF | 13.45% | 18.60% | 4.57% | 2.51% | -6.11% |
CIB0.DE VanEck Bionic Engineering UCITS ETF A | -11.68% | -10.00% | 5.16% | 2.09% | -8.46% |
Correlation
The correlation between NBTK.DE and CIB0.DE is 0.42, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.42 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.47 |
Correlation (All Time) Calculated using the full available price history since Dec 2, 2022 | 0.49 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBTK.DE vs. CIB0.DE — Risk / Return Rank
NBTK.DE
CIB0.DE
NBTK.DE vs. CIB0.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) and VanEck Bionic Engineering UCITS ETF A (CIB0.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBTK.DE | CIB0.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.44 | ||
| Sortino ratioReturn per unit of downside risk | +4.61 | ||
| Omega ratioGain probability vs. loss probability | 1.46 | 0.91 | +0.55 |
| Calmar ratioReturn relative to maximum drawdown | 8.66 | -0.47 | +9.12 |
| Martin ratioReturn relative to average drawdown | 25.74 | -1.10 | +26.84 |
Loading charts...
Drawdowns
NBTK.DE vs. CIB0.DE - Drawdown Comparison
The maximum NBTK.DE drawdown since its inception was -30.99%, roughly equal to the maximum CIB0.DE drawdown of -32.60%. Use the drawdown chart below to compare losses from any high point for NBTK.DE and CIB0.DE.
Loading charts...
Drawdown Indicators
| NBTK.DE | CIB0.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -30.99% | -32.60% | +1.61% |
Max Drawdown (1Y)Largest decline over 1 year | -6.24% | -23.47% | +17.23% |
Max Drawdown (3Y)Largest decline over 3 years | -29.35% | -32.60% | +3.25% |
Max Drawdown (5Y)Largest decline over 5 years | -30.99% | — | — |
Current DrawdownCurrent decline from peak | 0.00% | -26.17% | +26.17% |
Average DrawdownAverage peak-to-trough decline | -10.55% | -11.12% | +0.57% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.10% | 9.91% | -7.81% |
Volatility
NBTK.DE vs. CIB0.DE - Volatility Comparison
Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) has a higher volatility of 6.55% compared to VanEck Bionic Engineering UCITS ETF A (CIB0.DE) at 5.47%. This indicates that NBTK.DE's price experiences larger fluctuations and is considered to be riskier than CIB0.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBTK.DE | CIB0.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.55% | 5.47% | +1.08% |
Volatility (6M)Calculated over the trailing 6-month period | 14.43% | 12.99% | +1.44% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.28% | 17.33% | +1.95% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.31% | 18.05% | +2.26% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.05% | 18.05% | +4.00% |
NBTK.DE vs. CIB0.DE - Expense Ratio Comparison
NBTK.DE has a 0.40% expense ratio, which is lower than CIB0.DE's 0.55% expense ratio.
Dividends
NBTK.DE vs. CIB0.DE - Dividend Comparison
Neither NBTK.DE nor CIB0.DE has paid dividends to shareholders.
Frequently Asked Questions
NBTK.DE and CIB0.DE have a correlation of 0.42, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, NBTK.DE is cheaper at 0.40% per year. The better choice depends on whether you care most about return, fees, risk, or income.
NBTK.DE is cheaper with a 0.40% expense ratio, compared with 0.55% for CIB0.DE.
NBTK.DE tracks Nasdaq Biotechnology, while CIB0.DE tracks MVIS Global Bionic Healthcare ESG. They also come from different issuers: Invesco and VanEck. Their fees differ too: 0.40% for NBTK.DE and 0.55% for CIB0.DE.
Find the right allocation for NBTK.DE and CIB0.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer